(Press-News.org) A large international study aimed at improving the care of muscular dystrophy patients worldwide is being launched by physicians, physical therapists, and researchers at the University of Rochester Medical Center.
Neurologist Robert "Berch" Griggs, M.D., is heading the study of treatments for Duchenne muscular dystrophy, the most common form of the disease that affects children. The condition, which affects boys almost exclusively, progresses rapidly. Boys' symptoms start when they are toddlers; untreated, they end up in a wheelchair before they become teenagers. With today's best treatments, the disease, which affects about 28,000 boys and young men in the United States, is often fatal by the time a patient reaches his 20s or early 30s.
Despite decades of research, Griggs calls the current treatment landscape for the disease "chaotic." Recently he has identified 29 different treatment regimens in use by doctors around the world.
The new study is designed to eliminate the chaos. With at least $11 million in funding from the National Institute of Neurological Disorders and Stroke, Griggs and co-leader Kate Bushby, M.D., and investigators at 41 other institutions around the world will study the three treatments most commonly used today. The study will include 300 boys ages 4 through 7 throughout North America and Europe. Recruiting for the study will begin in the summer of 2011. Study funding is slated to reach close to $15 million.
The central feature of Duchenne muscular dystrophy is muscle weakness. The first symptoms, often seen around age 2 or 3, usually come when a boy has difficulty running, jumping, or climbing stairs. From there, even with treatment, the disease progresses very quickly. Boys are often confined to a wheelchair by age 9 or 10 because of weakness in their legs; their breathing muscles begin to fail and their heart muscle weakens dramatically in their teen years. Most patients begin receiving assisted breathing with a ventilator while they are teenagers.
About two-thirds of cases occur in families with a history of the disease – the genetic flaw responsible is passed from mother to son – but about one-third of cases occur spontaneously. That's because the disease's roots lie in a genetic flaw in the massive gene responsible for making a protein known as dystrophin, which helps make and keep muscles strong and stable. Weighing in at 2 million chemical bases, the gene is the biggest in the human body, and mutations are relatively frequent. In patients with a mutation, the body does not make enough dystrophin, and muscle fibers are gradually replaced with fat and other tissue.
In a study more than 20 years ago, in studies supported by the Muscular Dystrophy Association, Griggs and colleagues found that a daily dose of prednisone improves patients' lives dramatically. Yet Griggs has found that the treatment for Duchenne muscular dystrophy is chaotic because of concern about side effects. In a recent survey of more than 100 centers worldwide that specialize in treatment of the disease, only three were consistently using the recommended treatment – a daily dose of prednisone. Others were using prednisone intermittently or were using deflazacort; 10 weren't using steroids at all.
In the new study, patients will be randomly assigned to receive one of three steroid treatments: a) prednisone every day; b) prednisone every day for 10 days, alternating with 10-day periods without the drug; c) daily use of a steroid known as deflazacort, which is approved for use in Europe but not the United States. Neither the patients nor the researchers will be aware of the patients' treatment assignments until the conclusion of the trial.
Doctors have found that daily prednisone boosts muscle strength dramatically and that the effects are felt by patients and witnessed by parents within just 10 days. The drug boosts muscle mass by 20 percent and slows the degeneration of the muscles in patients with the disease. But concerns over side effects leave many doctors leery of prescribing the medication on a daily basis. Side effects can include weight gain, behavioral effects such as hyperactivity or irritability, and eventually loss of bone and even possibly fractures.
"People have worried about side effects of daily prednisone, and many people have felt there must be a better alternative," said Griggs, who is professor of Neurology, Medicine, Pediatrics, Pathology and Laboratory Medicine, and a member of the Center for Human Experimental Therapeutics. "Our study is designed to address exactly this question: What is the best balance between effective treatment and side effects?"
Children will be evaluated every six months for three to five years. Researchers will measure the breathing capacity of the patients, which is often an indicator of how long a patient will live; they will ask patients and parents how satisfied they are with the treatment; and they will measure how long it takes patients to stand up after lying down, which is an indicator of how long a patient will be able to walk.
"With a healthy child, if you clap your hands and tell him to stand up as quickly as he can, he's up on his feet in less than a second. With a child with Duchenne muscular dystrophy, it might take 30 times longer," said Griggs. "The child will roll onto his stomach, laboriously lift his bottom into the air, and slowly move his arms to one knee, then the other, bracing himself until he finally straightens up."
The study brings together two worldwide groups of physicians who specialize in the study of muscle disorders. The Muscle Study Group, with nearly three dozen sites in the United States, Canada, and Europe, is based in Rochester and headed by Griggs. The TREAT-NMD study group is a consortium of dozens of institutions across Europe and elsewhere that work together to study neuromuscular disorders. TREAT-NMD is headed by Bushby, who is Action Research Professor of Neuromuscular Genetics at Newcastle University in the United Kingdom.
Bushby and Griggs are leading the clinical aspects of the new study. Michael McDermott, Ph.D., professor of Biostatistics and Neurology, and Rabi Tawil, M.D., professor of Neurology, are co-leaders of biostatistical analysis and data management.
The team from Rochester also includes Barbara Herr, assistant professor of Neurology, manager of the U.S. portion of the project; associate project manager Christine Annis; Shree Pandya, lead U.S. physical therapist; Mary Brown, Heart Research Program manager; William Martens, data manager; and Emma Ciafaloni, M.D., associate professor of Neurology, who will lead the study of patients in Rochester.
Griggs is central to the international effort to find an effective treatment for the disease. Last week, for readers of the journal Lancet Neurology, Griggs was asked to put into perspective new findings from a study of the drug cyclosporine, which recently proved safe but not effective for patients. Griggs also served as the head of the data and safety monitoring board for a study of an investigational drug called ataluren conducted by PTC Therapeutics; earlier this year the company announced that the drug, though safe, failed to help patients in the ways doctors had hoped. Analysis of those data continues.
INFORMATION: END
Rochester leads international effort to improve muscular dystrophy treatment
2010-09-04
ELSE PRESS RELEASES FROM THIS DATE:
Satellite data reveal why migrating birds have a small window to spread bird flu
2010-09-04
In 2005 an outbreak of the H5N1 'bird flu' virus in South East Asia led to widespread fear with predictions that the intercontinental migration of wild birds could lead to global pandemic. Such fears were never realised, and now research published in the British Ecological Society's Journal of Applied Ecology reveals why the global spread of bird flu by direct migration of wildfowl is unlikely but also provides a new framework for quantifying the risk of avian-borne diseases.
The highly pathogenic H5N1 bird flu virus is primarily a disease of poultry, often resulting ...
First clinical trials successfully completed on potent new hepatitis C drug
2010-09-04
The first clinical trials on a new investigational drug being developed to treat infections caused by Hepatitis C virus have been successfully completed.
Completion of the initial phase (phase 1a) of trials of INX-189, discovered and first prepared by researchers at Cardiff University's Welsh School of Pharmacy in 2008, means the chances of it becoming an approved medicine have significantly improved.
Approximately 170 million people worldwide are affected with Hepatitis C, which can lead to liver cancer, cirrhosis and death. It is the leading cause of liver transplantation ...
Earth from space: Giant iceberg enters Nares Strait
2010-09-04
ESA's Envisat satellite has been tracking the progression of the giant iceberg that calved from Greenland's Petermann glacier on 4 August 2010. This animation shows that the iceberg, the largest in the northern hemisphere, is now entering Nares Strait – a stretch of water that connects the Lincoln Sea and Arctic Ocean with Baffin Bay.
The Petermann glacier in northern Greenland is one of the largest of the country's glaciers – and until August it had a 70 km tongue of floating ice extending out into the sea. The glacier regularly advances towards the sea at about 1 km ...
Rutgers-Camden professor engineers E. coli to produce biodiesel
2010-09-04
CAMDEN — One mention of E. coli conjures images of sickness and food poisoning, but the malevolent bacteria may also be the key to the future of renewable energy.
Desmond Lun, an associate professor of computer science at Rutgers University–Camden, is researching how to alter the genetic makeup of E. coli to produce biodiesel fuel derived from fatty acids.
"If we can engineer biological organisms to produce biodiesel fuels, we'll have a new way of storing and using energy," Lun says.
Creating renewable energy by making fuels, like making ethanol out of corn, has been ...
Americans struggle with long-term weight loss
2010-09-04
Only about one in every six Americans who have ever been overweight or obese loses weight and maintains that loss, according to Penn State College of Medicine researchers.
While that number is larger than most weight-loss clinical trials report, the majority of Americans are still unable to lose weight and keep it off. Identifying those who lose weight and successfully maintain that loss may aid health professionals in developing approaches to help others maintain weight loss, the researchers say.
Two-thirds of the United States adult population is overweight, defined ...
Publication of World Health Report 2000 'an act of remarkable courage,' says school expert
2010-09-04
Ten years on, Martin McKee reflects on report placed health system performance rankings firmly on political agenda.
Martin McKee, Professor of European Health at the London School of Hygiene & Tropical Medicine has contributed one of three commentaries appearing today in the journal Health Policy and Planning, each of which take a different perspective on the World Health Report 2000 on health systems (WHR2000).
It is ten years since the publication of WHR2000, a controversial document which many at the time believed had been published prematurely, and which introduced ...
GOES-13 satellite sees Hurricane Earl's clouds covering the US Northeast
2010-09-04
Hurricane Earl lashed the North Carolina coast last night and this morning, September 3, and is now headed for Cape Cod, Massachusetts. This morning's image from the GOES-13 satellite saw Hurricane Earl's clouds covering most of the northeastern U.S.
The Geostationary Operational Environmental Satellite known as GOES-13 captured an image of Hurricane Earl at 7:32 a.m. EDT this morning, September 3. The image clearly showed a huge Hurricane Earl northeast of North Carolina with cloud cover stretching over the northeastern U.S. A disorganized Fiona was also seen southeast ...
NASA hurricane researchers eye Earl's eye
2010-09-04
Hurricane Earl, currently a Category Two storm on the Saffir-Simpson scale with maximum sustained winds of 100 knots (115 miles per hour), continues to push relentlessly toward the U.S. East Coast, and NASA scientists, instruments and spacecraft are busy studying the storm from the air and space. Three NASA aircraft carrying 15 instruments are busy criss-crossing Earl as part of the agency's Genesis and Rapid Intensification Processes mission, or GRIP, which continues through Sept. 30. GRIP is designed to help improve our understanding of how hurricanes such as Earl form ...
AgriLife research hibiscus breeder comes up with the blue
2010-09-04
VERNON -- Dr. Dariusz Malinowski is seeing blue, and he is very excited.
For four years, Malinowski, an AgriLife Research plant physiologist and forage agronomist in Vernon, has been working with collaborators Steve Brown of the Texas Foundation Seed and Dr. William Pinchak and Shane Martin with AgriLife Research on a winter-hardy hibiscus breeding project.
The project was first a private hobby of the inventors and became a part of the strategic plan of the Texas AgriLife Research and Extension Center at Vernon in 2009. The flower commercialization is a part ...
Queen's study exposes cognitive effects of Parkinson's disease
2010-09-04
Researchers at Queen's University have found that people with Parkinson's disease can perform automated tasks better than people without the disease, but have significant difficulty switching from easy to hard tasks. The findings are a step towards understanding the aspects of the illness that affect the brain's ability to function on a cognitive level.
"We often think of Parkinson's disease as being a disorder of motor function," says Douglas Munoz, director of the Queen's Centre for Neuroscience Studies and a Canada Research Chair in Neuroscience. "But the issue is ...